Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.
Read more -
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash.
Read more -
GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK today announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all...
Read more -
James Shannon named GlaxoSmithKline Chief Medical Officer
James Shannon has been named GSK's Chief Medical Officer (CMO), effective 1 May. James will report to R&D Chairman Moncef Slaoui and be based in London. He will be account...
Read more -
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
GSK announces that Ms. Lynn Elsenhans and Ms. Jing Ulrich will join the Board of the Company with effect from 1 July 2012 as Non-Executive Directors.
Read more -
GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines
GlaxoSmithKline plc (GSK) and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease-causing ...
Read more -
GlaxoSmithKline receives European authorisation for Nimenrix™ (Meningococcal group A, C, W-135 and Y conjugate vaccine)
GlaxoSmithKline plc (GSK) announced today that the European Commission has granted marketing authorisation for Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine)...
Read more -
GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry
GSK and the University of Nottingham today formalised a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to cons...
Read more -
Children in Ghana to be vaccinated against diarrhoeal disease with the introduction of GSK’s Rotarix™ vaccine
GSK welcomes today's GAVI announcement that GSK's rotavirus vaccine, Rotarix, will be introduced into the newly started national vaccination programme in Ghana.
Read more -
FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma
GSK announced today that the U.S. FDA has approved Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy.
Read more -
Results announcement for the first quarter 2012
- Sales growth of +2% CER - Further R&D delivery, operational leverage and continued returns to shareholders - Core EPS 27.3p (+7%), dividend up 6% to 17p
Read more -
GlaxoSmithKline reaches agreement to divest non-core over-the-counter (OTC) brands in international markets for £164 million
GlaxoSmithKline Plc (GSK) today announced that it has reached agreement to divest the previously identified non-core OTC brands in its international markets to Aspen Pharmacare ...
Read more -
GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash
GlaxoSmithKline plc today confirms that it made an offer to the Board of Directors of Human Genome Sciences on 11th April proposing to acquire all of the outstanding shares of H...
Read more -
GSK provides update on corporate responsibility commitments in 2011 report
GSK has today published its Corporate Responsibility Report, in which the company reiterates its commitment to operate responsibly, openly and transparently and sets out advance...
Read more -
GSK receives further data from phase lll studies of albiglutide in type 2 diabetes
GSK today announced that topline results have been received from seven of the eight ‘Harmony’ Phase III studies investigating the use of albiglutide in type 2 diabet...
Read more -
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment-naïve HIV patients.
Read more -
GlaxoSmithKline to increase its ownership in Theravance
GSK and Theravance, Inc. announced they have entered into a stock purchase agreement, under which Theravance will issue, and GSK will acquire, 10,000,000 shares of Theravance co...
Read more -
GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD
GSK and Theravance, Inc. today announced the registrational programme for Relovair™ is now complete. In addition, results from two studies for the once-daily investigation...
Read more -
GSK confirms significant investments in UK manufacturing: Ulverston in Cumbria selected as site of new biopharmaceutical factory
GSK today confirmed that it will invest more than £500m in the UK across its manufacturing sites to increase production of key active ingredients for its pharmaceutical pro...
Read more -
GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas
GSK announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit; risk assessm...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
